Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib vs Alendronate in Postmenopausal Osteoporosis
NCT01552122Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- May 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of odanacatib in postmenopausal osteoporosis, sponsored by Merck & Co.. Planned start May 2012; status: withdrawn.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01552122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01552122.